Wellington Management Group LLP Has $1.38 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Wellington Management Group LLP grew its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 46.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,813 shares of the company’s stock after purchasing an additional 22,096 shares during the quarter. Wellington Management Group LLP owned approximately 0.10% of Kiniksa Pharmaceuticals worth $1,381,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Teacher Retirement System of Texas lifted its holdings in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after buying an additional 719 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Franklin Resources Inc. boosted its position in shares of Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock worth $302,000 after purchasing an additional 1,680 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock valued at $3,947,000 after purchasing an additional 3,673 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on KNSA shares. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $37.17.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares of the company’s stock, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the completion of the sale, the chief financial officer now owns 23,382 shares in the company, valued at $540,124.20. This trade represents a 32.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,766 shares of company stock worth $1,756,375. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA opened at $19.31 on Monday. The business’s 50-day simple moving average is $20.97 and its 200-day simple moving average is $21.60. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15. The stock has a market capitalization of $1.40 billion, a PE ratio of -137.92 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same quarter last year, the company earned $0.35 EPS. The firm’s quarterly revenue was up 46.9% compared to the same quarter last year. On average, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.